| Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma CHY van Beurden-Tan, MG Franken, HM Blommestein, CA Uyl-de Groot, ... Journal of Clinical Oncology 35 (12), 1312-1319, 2017 | 139 | 2017 |
| Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study HM Blommestein, SGR Verelst, PC Huijgens, NMA Blijlevens, ... Annals of hematology 91, 1945-1952, 2012 | 70 | 2012 |
| Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with … GS Sonke, A Van Ommen-Nijhof, N Wortelboer, V van der Noort, ... Journal of Clinical Oncology 41 (17_suppl), LBA1000-LBA1000, 2023 | 64 | 2023 |
| Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS) SGR Verelst, HM Blommestein, S De Groot, S Gonzalez-McQuire, ... Hemasphere 2 (4), e45, 2018 | 47 | 2018 |
| Balancing the optimal and the feasible: a practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch … S de Groot, N van der Linden, MG Franken, HM Blommestein, ... Value in Health 20 (4), 627-636, 2017 | 47 | 2017 |
| A cost‐effectiveness analysis of real‐world treatment for elderly patients with multiple myeloma using a full disease model HM Blommestein, SGR Verelst, S de Groot, PC Huijgens, P Sonneveld, ... European journal of haematology 96 (2), 198-208, 2016 | 46 | 2016 |
| Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis HM Blommestein, CHY van Beurden-Tan, MG Franken, CA Uyl-de Groot, ... Haematologica 104 (5), 1026, 2019 | 44 | 2019 |
| The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands A Leunis, HM Blommestein, PC Huijgens, NMA Blijlevens, ... Leukemia Research 37 (3), 245-250, 2013 | 44 | 2013 |
| Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international health technology assessment agencies O Ciani, B Grigore, H Blommestein, S de Groot, M Möllenkamp, S Rabbe, ... Medical Decision Making 41 (4), 439-452, 2021 | 38 | 2021 |
| A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry HM Blommestein, MG Franken, CA Uyl-de Groot Pharmacoeconomics 33, 551-560, 2015 | 36 | 2015 |
| Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal B Pongiglione, A Torbica, H Blommestein, S de Groot, O Ciani, S Walker, ... International journal of technology assessment in health care 37 (1), e62, 2021 | 31 | 2021 |
| Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma B Leeneman, MG Franken, VMH Coupé, MP Hendriks, W Kruit, ... European Journal of Surgical Oncology 45 (5), 825-831, 2019 | 30 | 2019 |
| Cost‐effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population‐based study HM Blommestein, DE Issa, M Pompen, G Ten Hoor, M Hogendoorn, ... European journal of haematology 92 (5), 398-406, 2014 | 25 | 2014 |
| Microcosting study of rituximab subcutaneous injection versus intravenous infusion J Mihajlović, P Bax, E van Breugel, HM Blommestein, M Hoogendoorn, ... Clinical Therapeutics 39 (6), 1221-1232. e4, 2017 | 23 | 2017 |
| Changes in survival in de novo metastatic cancer in an era of new medicines M Luyendijk, O Visser, HM Blommestein, IHJT de Hingh, FJP Hoebers, ... JNCI: Journal of the National Cancer Institute 115 (6), 628-635, 2023 | 22 | 2023 |
| Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy: an evidence review group perspective of a … NC Büyükkaramikli, HM Blommestein, R Riemsma, N Armstrong, FJ Clay, ... Pharmacoeconomics 35, 1211-1221, 2017 | 21 | 2017 |
| Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands HM Blommestein, S de Groot, MJ Aarts, P Vemer, R de Vries, ... Leukemia research 50, 37-45, 2016 | 20 | 2016 |
| Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first-and second … S De Groot, HM Blommestein, WK Redekop, S Sleijfer, L Kiemeney, ... PloS one 12 (5), e0177364, 2017 | 14 | 2017 |
| Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of … MG Franken, JG Gaultney, HM Blommestein, PC Huijgens, P Sonneveld, ... Value in health 17 (2), 245-253, 2014 | 12 | 2014 |
| Are we making progress? Survival in plasma cell malignancies in the era of novel treatments a population based study of 17.790 patients in The Netherlands S Verelst, H Karim-Kos, H Blommestein, P Sonneveld Haematologica 97, 242-242, 2012 | 12 | 2012 |
